More: American Academy of Neurology (AAN) 60th Annual Meeting

Key Findings in Multiple Sclerosis Presented at the 60th Annual Meeting of the American Academy of Neurology CME/CE

April 12 - 19, 2008, Chicago, Illinois

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the American Academy of Neurology.

Release Date: May 30, 2008; Valid for credit through May 30, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 nursing contact hours (0.75 contact hours are in the area of pharmacology);
Pharmacists - 1.0 ACPE continuing education credits for pharmacists (0.1 CEUs)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME/CE Activity

  1. New Data on Disease-modifying Therapies for Multiple SclerosisThis article discusses results of key clinical trials presented at the 60th annual AAN meeting on currently available disease-modifying therapies for MS and the potential implications for clinical practice.Author: Andrew N Wilner, MD, FAAN, FACP; Expert Reviewer, Mark J. Tullman, MD (Conference Coverage, May 30 2008)
  2. New and Emerging Therapies for Multiple SclerosisThis article discusses data on emerging therapies for MS presented at the 60th Annual AAN Meeting and how these therapies may fill currently unmet needs in the pharmacologic management of MS.Author: Andrew N Wilner, MD, FAAN, FACP; Expert Reviewer, Mark J. Tullman, MD (Conference Coverage, May 30 2008)
  3. New Data on Comorbidities and Quality of Life in Patients With Multiple SclerosisThis article discusses highlights of data presented at the 60th Annual Meeting of the AAN on comorbidities and quality of life in patients with multiple sclerosis.Howard L. Zwibel, MD; Andrew N Wilner, MD, FAAN FACP (Conference Coverage, May 30 2008)

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Academy of Neurology. These materials and the related activity are not sanctioned by the American Academy of Neurology or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Teva
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Evaluate the results of clinical trials focused on benefits of early therapy with disease-modifying agents
  2. Discuss new data on emerging injectable and oral therapies for patients with MS
  3. Recognize comorbidities commonly associated with MS
  4. Identify key factors that impact quality of life in patients with MS
Authors and Disclosures

Mark J. Tullman, MD
Disclosure: Mark J. Tullman, MD, has disclosed that he has received grant support from Novartis and consulting or lecture fees from Biogen Idec, EMD Serono, and Teva Neuroscience.


Howard Zwibel, MD
Disclosure: Howard Zwibel, MD has disclosed that he has received grants for clinical research and educational activities from Teva Neuroscience. Dr. Zwibel has also disclosed that he has served as an advisor or consultant to Bayer HealthCare Pharmaceuticals, Biogen Idec, EMD Serono, and Teva Neuroscience.


Stephanie Kushner, PhD
Disclosure: Stephanie Kushner, PhD, is a member of the professional editorial group at Medscape and has reported no financial relationships relevant to the development of CME activities.


Andrew N. Wilner, MD, FAAN, FACP
Disclosure: Andrew N. Wilner, MD, FAAN, FACP, has disclosed that he owns stock in GlaxoSmithKline.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

 
ACPE logoMedscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medscape is accredited by the American Council on Pharmacy Education as a provider of continuing pharmacy education. Medscape designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the American Council on Pharmacy Education (Universal Program Number 461-000-08-018-H01-P).

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.